Hologen
Hologen is a private AI-driven healthcare research company that applies AI to CNS drug discovery, focusing on neuroprotective therapeutics. It serves pharmaceutical and biotech partners through strategic co-development and licensing deals, exemplified by its $200M+ joint venture with MeiraGTx for the AAV-GAD Parkinson's program.
- Company typePrivate
- Founded2023
- HeadquartersSt. Peter Port
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Hologen does
Hologen is a private AI-driven healthcare research company founded in 2023 and headquartered in St. Peter Port, Guernsey. The company is positioned at the intersection of artificial intelligence and central nervous system (CNS) drug discovery, with a stated focus on neuroprotective therapeutics for neurological conditions. Its core offering is described as an 'AI-CNS Drug Discovery Platform' that applies AI capabilities to identify and develop neuroprotective drug candidates, in collaboration with genetic medicine platforms. The company also describes its work in terms of disease modeling, clinical trial planning, and personalized intervention design, though no specific product modules, technical architecture, or platform components have been publicly disclosed.
Hologen's business model is built around strategic partnerships and licensing arrangements with pharmaceutical and biotechnology companies. The company provides AI discovery capabilities and substantial capital commitments in exchange for co-development rights and potential milestone/royalty payments, generating revenue through licensing and royalty streams. Its only disclosed commercial relationship is a joint venture with MeiraGTx Holdings plc, a clinical-stage genetic medicine company, for the AAV-GAD Parkinson's program. Under this agreement, Hologen committed $200 million upfront plus up to $230 million in additional committed funding. The company targets enterprise customers in the pharmaceutical and biotech sector that are seeking to accelerate neuroprotective drug discovery for neurological conditions.
The company operates with 11-50 employees under founder and CEO Roland W. Tegeder. Its primary customer segment is horizontal across pharmaceutical and biotech business units, addressing the pain point of integrating AI to accelerate neuroprotective drug discovery and reduce CNS therapy development timelines. Notably, Hologen's public web presence is currently inactive (all pages return 404), and no revenue, cap table, headcount specifics, or detailed technical platform information has been disclosed in the available source material.
Hologen firmographics
Firmographics- Name
- Hologen
- Website
- https://hologen.ai
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Hologen is a private AI-driven healthcare research company that applies AI to CNS drug discovery, focusing on neuroprotective therapeutics. It serves pharmaceutical and biotech partners through strategic co-development and licensing deals, exemplified by its $200M+ joint venture with MeiraGTx for the AAV-GAD Parkinson's program.
- Ownership category
- akta.pro rank
Hologen industry classification
Industry- Product category
- AI Drug Discovery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
Keywords
Where Hologen is headquartered
LocationHeadquarters
- HQ city
- St. Peter Port
Markets served
Hologen business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Strategic Partnerships & Licensing: Hologen generates revenue through strategic collaboration and licensing agreements with pharmaceutical companies, providing AI capabilities and contributing funding in exchange for development rights and potential milestone/royalty payments. The company committed $200M upfront plus up to $230M in committed funding to the MeiraGTx joint venture.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Hologen product offering
Product offeringCore offering
Hologen is an AI-driven drug discovery company focused on developing neuroprotective therapeutics for central nervous system (CNS) disorders. The company partners with pharmaceutical and genetic medicine companies through joint ventures and licensing agreements, providing AI capabilities and capital to accelerate development of neurological therapies, including gene therapies for Parkinson's disease.
Product overview
Hologen is an AI company focused on CNS (central nervous system) and drug discovery, as evidenced by a strategic collaboration with MeiraGTx in ophthalmology and CNS/AI, including a $200 million joint venture for the AAV-GAD Parkinson's program.
Differentiator
Problem solved
Functional benefit
Products and services
- AI-CNS Drug Discovery Platform
- AAV-GAD Parkinson's Program (Joint Venture with MeiraGTx) Strategic co-development program for gene therapy targeting Parkinson's disease, executed via joint venture with MeiraGTx Holdings plc; Hologen provides AI capabilities and substantial capital to advance the AAV-GAD program.
Companies that use Hologen
Customer profileSegments1 record
Ideal customer profiles1 record
Hologen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Hologen partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- MeiraGTx Holdings plcflagshipHologen formed a joint venture with MeiraGTx for CNS/AI drug discovery, specifically targeting the AAV-GAD Parkinson's program. Hologen contributed $200 million upfront plus up to $230 million in committed funding. The collaboration was finalized in 2026 (April 2026) after initial announcement in 2025. MeiraGTx is a clinical-stage genetic medicine company headquartered in New York, advancing late-stage pipeline programs including gene therapies for Parkinson's disease and achromatopsia.
Scale indicators3 records
Recent moves3 records
Expansion highlights4 records
Hologen competitors and assessment
Company assessmentDirect peers
- Insitro: ML-enabled drug discovery company building predictive models from human data to accelerate therapeutic development, with CNS and neurodegenerative indications in its pipeline. Closely comparable business model pairing AI/ML with pharma partnerships.
- Exscientia: AI-native pharma company using end-to-end AI platforms to design and develop novel therapeutics, with a partner-driven co-development model similar to Hologen's GTM. Direct AI drug discovery peer with overlapping commercial structure.
- BenevolentAI: AI drug discovery platform with explicit CNS and neurodegenerative disease focus, combining biomedical knowledge graphs with ML to identify targets. Highly comparable in AI x CNS intersection.
- Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with ML to identify novel therapeutics, including CNS programs. Direct competitor in AI-native biotech with overlapping approach of using computation to compress discovery timelines.
- Verge Genomics: AI-driven drug discovery company focused specifically on neurodegenerative diseases including Parkinson's and ALS. Closely aligned with Hologen's CNS/AI therapeutic focus, though Verge emphasizes human genomics data rather than genetic medicine partnerships.
Regional players
- uniQure: Gene therapy company developing AAV-based therapies for CNS disorders including Huntington's disease. Comparable therapeutic modality (AAV gene therapy) for CNS indications, intersecting with Hologen's domain through the AAV-GAD program.
- Cerevel Therapeutics: CNS-focused therapeutics company (acquired by AbbVie) developing treatments for neuroscience disorders including Parkinson's disease. Adjacent CNS therapeutics peer operating in the same disease area Hologen targets.
- Voyager Therapeutics: Clinical-stage gene therapy company focused on CNS disorders using AAV vectors, including Parkinson's programs. Operates in the same AAV-CNS intersection where Hologen's AAV-GAD program is positioned.
Others
- MeiraGTx Holdings: Clinical-stage genetic medicine company and Hologen's flagship JV partner for the AAV-GAD Parkinson's program. Not a direct competitor but the partner through which Hologen currently monetizes its AI capabilities in CNS/gene therapy.
Broad incumbents
- Isomorphic Labs: Alphabet-owned AI drug discovery company applying DeepMind's protein folding and ML capabilities to therapeutic discovery. Larger, better-capitalized incumbent in the same AI-drug-discovery category that competes for the same partner ecosystem.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks1 record
Key highlights5 records
Customer concentration
Hologen social profiles
Digital presenceHologen financial estimates
Financial estimateRevenue estimate
Valuation estimate
Hologen leadership team
Management profileNumber of profiles
Profiles1 record
Hologen funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Hologen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Hologen
What does Hologen do?
Hologen is an AI-driven drug discovery company focused on developing neuroprotective therapeutics for central nervous system (CNS) disorders. The company partners with pharmaceutical and genetic medicine companies through joint ventures and licensing agreements, providing AI capabilities and capital to accelerate development of neurological therapies, including gene therapies for Parkinson's disease.
Is Hologen a public or private company?
Hologen is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Hologen founded?
Hologen was founded in 2023. It employs 11 to 50 people.
Where is Hologen based?
Hologen is headquartered in St. Peter Port.
How does Hologen make money?
One revenue line is on record: strategic Partnerships & Licensing.
Who are Hologen's main competitors?
Direct peers on record are Insitro, Exscientia, BenevolentAI, Recursion Pharmaceuticals and Verge Genomics. Regional players are uniQure, Cerevel Therapeutics and Voyager Therapeutics. MeiraGTx Holdings is listed as an others. Isomorphic Labs is listed as a broad incumbent.
Does Hologen have an API?
No public API is recorded for Hologen.
What industry is Hologen in?
Hologen's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 2834.